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ABSTRACT
Histoplasmosis is the most common endemic mycoses among HIV-infected people. Patients with suppressed cell immunity 
mainly due to HIV are at increased risk of disseminated disease. Dermatological manifestations of immune reconstitution 
inflammatory syndrome (IRIS) and cutaneous manifestations of histoplasmosis similar to an IRIS event have been previously 
described. We report the case of a 43-year-old male who presented with cutaneous disseminated histoplasmosis due to 
Histoplasma capsulatum var. capsulatum 4 months after the onset of the antiretroviral therapy and some improvement in 
the immune reconstitution. After 2 weeks of amphotericin B and itraconazole therapy, the scheduled treatment involved 
fluconazole maintenance therapy, which resulted in an improvement of his skin lesions. 
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INTRODUCTION
Histoplasmosis is a systemic fungal infection caused 
by the intracellular dimorphic fungus Histoplasma 
capsulatum. It is endemic in the USA, but has been 
reported in South America and Africa.1,2 Clinical 
presentation of histoplasmosis is nonspecific, and 
95% of the patients with H. capsulatum infections 
are asymptomatic. Therefore, the clinical presentation 
of histoplasmosis may vary from asymptomatic to 
disseminated disease depending on the patient’s 
immunological status.3-5 Histoplasmosis is an 
AIDS-defining opportunistic infection presenting as 
an invasive form.6-8
Immune reconstitution inflammatory syndrome 
(IRIS)-related dermatological manifestations of HIV 
are common, and cutaneous histoplasmosis following 
antiretroviral therapy (ART) was previously described.9,10 
We report the case of an HIV-infected patient who 
presented with cutaneous histoplasmosis 4 months 
after the onset of ART, with viral suppression and 
immunological recovery, which were consistent with 
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an IRIS event. The clinical manifestations, diagnosis, 
and management of histoplasmosis IRIS are reviewed.
CASE REPORT
A 43-year-old male, known to be HIV infected 
for 6 months, was referred by his primary HIV clinic 
to the Mulago National Referral Hospital in Uganda 
with a 2-month history of nodular lesions in the face. 
Skin findings were also associated with a nonproductive 
cough, dyspnea, and fever over the past month. 
The skin nodules started to appear 2 months after ART 
was initiated, and began as small lesions on the nose 
that progressed in size and number throughout the 
face. The patient was initially and empirically treated 
with azithromycin with the hypothesis of atypical 
Mycobacterium cuneiform infection, with mild clinical 
improvement. The patient was started on ART (tenofovir 
300 mg/day, lamivudine 300 mg/day, and efavirenz 
600 mg/day) and trimethoprim/sulfamethoxazole for 
prophylaxis at the time of HIV infection diagnosis.
His past medical history included the diagnosis 
of HIV infection 6 months earlier, with a nadir CD4 
determination of 42 cells/mm3.
On examination, his general condition was 
fair ,  with no lymphadenopathy, normal v ital 
signs, and a clear chest exam. Skin examination 
showed hyper-pigmented nodular lesions on his 
face with varying diameters. The larger lesions 
(approximately 2 cm × 3.5 cm) were on the nose 
(Figure 1). The abdominal examination did not reveal 
hepatosplenomegaly.
The patient’s chest x-ray was normal; thoracic 
computed tomography was not performed. Laboratory 
investigations revealed normal hematological indices 
and serum electrolytes.
The serological test for HIV was positive. The viral load 
for HIV was undetectable, and CD4 was 108 cells/mm3. 
Diagnoses of Kaposi sarcoma, bacillary angiomatosis, 
squamous cell carcinoma, and invasive mycosis were 
considered. A punch biopsy was obtained from two 
lesions of the face. Histological examination showed 
granulomatous dermatitis with round cytoplasmic 
organelles within the macrophages consistent with 
H. capsulatum var. capsulatum (Figure 2 and Figure 3).
A diagnosis of unmasking mucocutaneous 
histoplasmosis IRIS was made. The patient was 
started on intravenous amphotericin B (1 mg/kg) daily 
and oral itraconazole (400 mg daily) for 2 weeks, 
besides potassium and magnesium supplementation, 
paracetamol, and 3 L of intravenous saline daily during 
hospitalization. Antiretroviral therapy was continued. 
The patient’s renal function and complete blood count 
remained within normal ranges during the course of 
amphotericin.
On completion of the amphotericin treatment, the 
patient’s symptoms regressed and he was discharged 
after 14 days on oral fluconazole 400 mg daily, as 
he could not afford the high cost of itraconazole. 
The patient has been monitored monthly since hospital 
discharge and continues to improve on fluconazole 
therapy and ART. His clinical status is favorable; the 
skin lesions are healing but leaving enduring scarring 
and partial destruction of the nasal cartilage (Figure 4).
DISCUSSION
Histoplasmosis is a common AIDS-defining 
illness11 caused by H. capsulatum, a dimorphic fungus, 
which is distributed worldwide and is endemic in both 
South and North America, particularly in the Ohio and 
Mississippi river valleys in the latter. H. capsulatum var. 
capsulatum and H. capsulatum var. duboisii are the 
variants that cause human disease.12,13 H. capsulatum 
var. duboisii is described only in Africa; however, 
both variants are endemic in Uganda. Spores of 
H. capsulatum are found in the soil and caves inhabited 
by birds and bats.4
Primary lung infection results from the inhalation 
of microconidia, which turn into yeast in the lungs. 
The yeast is then spread to the reticuloendothelial 
system within 2-3 weeks by tissue macrophages.5,14
The clinical presentation of histoplasmosis depends 
on the integrity of the immune system. Nearly 95% 
of the infected people with normal immune systems 
will remain asymptomatic,1,15 and the remaining will 
present acute or chronic pulmonary histoplasmosis.15
However, individuals with immunosuppressive 
disorders affecting cell-mediated immunity may 
present with disseminated histoplasmosis. HIV-infected 
people with a CD4 cell count below 100 cells/mm3 are 
at increased risk for the development of disseminated 
histoplasmosis,14,15 which was the case with our 
patient, who had a CD4 cell count of 42 cells/mm3.
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Figure 1. Cutaneous lesions throughout on the face before the antifungal treatment.
Cough, fever,  mala ise,  weight loss,  and 
hepatosplenomegaly represent the most common 
clinical features of disseminated histoplasmosis. 
Although gastrointestinal symptoms are rare, 70% 
of patients with this disease present gastrointestinal 
invo lvement  on autopsy . 1,16,17 D i s seminated 
histoplasmosis may be misdiagnosed as tuberculosis 
or malaria due to the nonspecificity of the symptoms 
in many health facilities, especially when the laboratory 
work-up is limited.
Autopsy and Case Reports 2016;6(4):27-33
Unmasking histoplasmosis immune reconstitution inflammatory syndrome in a patient recently started on antiretroviral therapy
30
Cutaneous presentation is found in 6% of 
patients with disseminated histoplasmosis.5,16,18 
However, mucocutaneous involvement varies by 
geographic location and occurs more commonly in AIDS 
patients, particularly in those with suspected IRIS.9,19 
A review of the clinical manifestations of disseminated 
histoplasmosis showed that the dermatological 
manifestation was more common and more extensive 
in Brazilian HIV-infected people when compared with 
North American counterparts.9 A similar tropism for 
skin and lymph nodes involvement has been observed 
in African histoplasmosis. Nacher et al.20 described a 
Figure 2. Photomicrography of the skin biopsy. A - Normal epidermis and infiltrated dermis (H&E, 100X); B, C, and 
D - Small, oval, narrow based yeasts consistent with Histopolasma capsulatum (H&E, 400X).
Figure 3. Photomicrography of the skin biopsy showing in A - multiple oval-shaped structures consistent with 
Histoplasma sp (Grocott, 1000X); in B -  PAS staining spores appearing as round or oval structures within the 
cytoplasm of the macrophages (PAS, 1000X).
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higher incidence of disseminated histoplasmosis among 
patients that recently started on antiretroviral therapy, 
suggesting that this treatment can lead to unmasking 
IRIS. Passos et al.21 reported the case of paradoxical 
histoplasmosis IRIS following re-introduction of HAART 
in a Brazilian patient that voluntarily stopped his HAART 
and itraconazole prophylaxis. Breton et al.22 presented 
four patients with HIV-associated with unmasking 
and paradoxical disseminated histoplasmosis IRIS. 
At the time of presentation, our patient was on ART 
for 4 months, with immunological response and 
viral suppression, which are features consistent with 
unmasking IRIS.23,24
Diverse diagnostic modalities with varying 
sensitivity and specificity are available for the diagnosis 
of histoplasmosis, including tissue cultures, fungal 
stains, and serologic tests for detecting antibodies or 
antigens.5 Isolation of the pathogen in culture media 
(BACTEC™, Becton Dickinson, Sabouraud’s agar) is 
the gold standard for the diagnosis; however, the 
isolation takes more than 4 weeks, which limits its 
clinical applicability.25,26 Culture specimens can be 
obtained from urine, blood, sputum, lymph nodes, 
bronchoalveolar lavage, or bone marrow aspirate. 
Serology, although rapid and sensitive, is limited by low 
specificity because of the cross-reactivity with other 
fungi. Moreover, serology shows reduced sensitivity in 
disseminated histoplasmosis and immune suppressed 
patients, and the antibodies remain elevated for an 
extended time, limiting its use for differentiating 
relapse from an earlier infection.25-27 Urinary antigen 
testing offers rapid diagnosis with the sensitivity of 
90% for patients with disseminated histoplasmosis and 
can be used for monitoring the response to therapy.2,25 
Assays of histoplasma antigen in our patient’s body 
fluids were not performed as they are not readily 
available in Uganda.
Histological examination with the aid of Giemsa, 
Wright, the periodic acid of Schiff (PAS), or methenamine 
silver stainings provides a less expensive and rapid 
diagnosis, but has loose sensitivity for the antigenic 
tests. H. capsulatum appears in macrophages as ovoid 
or spherical uninucleate yeasts of 2–4 micrometers 
with narrow base buds.5 Pneumocystis jiroveci, 
Toxoplasma gondii, Penicillium marneffei, Candida 
glabrata, Leishmania donovani, and Cryptococcus 
neoformans may appear similar to H. capsulatum on 
direct microscopy. However, most of the serologic 
tests are expensive and barely available in Uganda. 
In our case, the diagnosis was based on the histologic 
examination of the skin biopsy.
Our patient received amphotericin B and 
itraconazole for 2 weeks, which is the regimen of choice 
for the management of disseminated histoplasmosis 
where liposomal or lipid formulations of amphotericin 
are not available.5,15 The Infectious Diseases Society 
of America guidelines recommend that patients with 
disseminated histoplasmosis and HIV should be treated 
with amphotericin B (0.7-1 mg/kg per day) for 2 weeks 
followed by itraconazole for at least 12 months.15 
Secondary prophylaxis with itraconazole maintenance 
therapy (200 mg/day) should be considered for 
extended periods of immunosuppression. Some 
literature data suggest withdrawing prophylaxis at 
CD4 > 150 cells/mm3.12,28 Upon discharge, this patient 
was started on fluconazole instead of itraconazole 
because of the cost of the treatment and the 
unavailability of free dispensing of itraconazole in 
Uganda. Although fluconazole has some activity 
against histoplasmosis, it is less efficacious than 
itraconazole, and has been associated with higher 
resistance rates.29-31
Antiretroviral therapy substantially improves the 
outcomes of HIV-infected people with disseminated 
histoplasmosis. Additionally, there is evidence 
suggesting that patients on ART who develop 
Figure 4. Skin examination after 6 months of treatment.
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disseminated histoplasmosis IRIS should continue on 
the ART.32-34
Literature data recommend continuing prophylaxis 
until the clinical and the laboratory results normalize.29 
Our patient received fluconazole 400 mg daily and was 
monitored monthly in the outpatient clinic. We intend 
to taper the dose of fluconazole to 200 mg at the 
twelfth week and withdraw it when the CD4 count 
exceeds 150 cells/mm3 and, if available, a normal 
laboratory antigen assay is achieved. Although our 
patient is showing immunological improvement, there 
is a risk of relapse since he is receiving a less suitable 
drug. Additional studies are needed concerning the 
management and length of treatment of histoplasmosis 
with fluconazole to provide a second choice where 
itraconazole remains prohibitively expensive. We also 
recommend that clinicians should consider a diagnosis 
of cutaneous histoplasmosis in HIV-infected persons 
that present with Kaposi sarcoma-like lesions.
Note: The patient signed an informed consent 
authorizing the publication the pictures of his face.
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